Pneumococcal 13-valent conjugate vaccine (Pfizer)

13价肺炎球菌多糖结合疫苗

Report date: 2025/06/16 17:46:15

Base Information

Drug NamePneumococcal 13-valent conjugate vaccine (Pfizer)
Drug Alias Name沛儿13Prevnar 13Prevenar 13Prevnar 13/Prevenar 13PCV13 +[6] 
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaHealthy AgingIgG Deficiency +[20] 
Global Approved IndicationsPneumonia, BacterialPneumococcal Infections
Approved Indications in ChinaPneumococcal Infections
Original Approved Country/TerritoryEU
Original Approved Date2009/12/09
Country/TerritoryCanadaUnited StatesVietnam +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer LtdWyeth Pharmaceuticals IncWyeth Holdings Corp +[12] 
Inactive CompaniesWyeth LlcGlaxosmithkline PlcUniversity Of Siena +[10] 
Active IndicationsPrimary mediastinal B cell lymphomaMeningitisCholangiocarcinoma +[12] 
Inactive IndicationsHealthy AgingIgG DeficiencyHIV-Associated Lipodystrophy Syndrome +[8] 

Other Information

ATC CodeJ07AL02
Related LinksWikipedia